• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Indian Journal of Endocrinology and Metabolism >Long-term response to recombinant human growth hormone therapy in Indian children with growth hormone deficiency
【24h】

Long-term response to recombinant human growth hormone therapy in Indian children with growth hormone deficiency

机译：印度生长激素缺乏症儿童对重组人生长激素治疗的长期反应

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Growth hormone deficiency (GHD) remains the most common indication for use of recombinant human growth hormone (rhGH) therapy in clinical practice. However, there is a paucity of studies focusing on long-term response to rhGH therapy in the Indian context. Aim: To determine the response to rhGH therapy and its predictors in children with GHD followed up at a tertiary care center in North India. Materials and Methods: We performed a retrospective review of the records of children with GHD who received rhGH therapy for at least 1 year. The relevant anthropometric, biochemical and radiological data at baseline and follow-up were recorded. Results: A total of 99 children (64 boys, 35 girls; 61 isolated GHD, 38 multiple pituitary hormone deficiency) were studied. The mean (±SD) age and height SDS at treatment initiation were 12.4 (±3.0) years and ?4.0 (±1.1) respectively, while median (IQR) serum insulin-like growth factor 1 (IGF-1) and peak growth hormone level on clonidine stimulation were 73 (25-167) ng/ml and 1.1 (0.4-3.6) ng/ml respectively. The height velocity was highest during the first year of treatment (10.6 ± 3.0 cm/year), declining to 8.7 ± 2.7 and 7.9 ± 2.2 cm/year during second and third year, respectively. Over the subsequent years, there was further graded fall in height velocity, declining to 4.8 ± 3.6 cm/year (n = 2) during the seventh year. The height gain during first year was negatively correlated with age at initiation of treatment, baseline height SDS, baseline serum IGF-1 and peak serum GH level on GH stimulation test, while it showed a positive correlation with bone age delay at baseline. Only baseline height SDS was found to have a significant negative correlation with height gain during the second year. Conclusions: This study provides data on long-term response to rhGH therapy and its predictors in Indian children with GHD.
机译：背景：生长激素缺乏症（GHD）仍然是临床实践中使用重组人生长激素（rhGH）治疗的最常见指征。然而，在印度背景下，针对rhGH治疗的长期反应的研究很少。目的：确定在印度北部的一家三级医疗中心对GHD儿童对rhGH治疗的反应及其预测因素。材料和方法：我们对接受rhGH治疗至少1年的GHD儿童的记录进行了回顾性回顾。在基线和随访时记录相关的人体测量学，生化和放射学数据。结果：共研究了99名儿童（男64例，女35例; GHD 61例，垂体激素38缺乏症）。开始治疗时的平均（±SD）年龄和身高SDS分别为12.4（±3.0）岁和？4.0（±1.1），而中位（IQR）血清胰岛素样生长因子1（IGF-1）和峰值生长激素可乐定刺激水平分别为73（25-167）ng / ml和1.1（0.4-3.6）ng / ml。在治疗的第一年，身高速度最高（10.6±3.0 cm /年），第二年和第三年分别下降到8.7±2.7和7.9±2.2 cm /年。在随后的几年中，高度速度进一步下降，在第七年下降到4.8±3.6厘米/年（n = 2）。第一年的身高增长与开始治疗时的年龄，基线身高SDS，基线血清IGF-1和GH刺激试验中的血清GH水平呈负相关，而与基线时的骨龄延迟呈正相关。第二年仅发现基线身高SDS与身高增加显着负相关。结论：这项研究提供了对印度GHD儿童对rhGH治疗的长期反应及其预测因子的数据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号